Compare

China SXT Pharmaceuticals, Inc. vs Longeveron Inc. vs Dare Bioscience, Inc. vs IGC Pharma, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearChina SXT Pharmaceuticals, Inc.
SXTC
Longeveron Inc.
LGVN
Dare Bioscience, Inc.
DARE
IGC Pharma, Inc.
IGCLast annual report: year ended 2025-03-31
Year ended2026-03-312025-12-312025-12-312025-03-31
Revenue$1.14M$1.20M$1.03M$1.27M
Revenue growth (YoY)-34.6%-49.9%n/m-5.5%
Gross margin21.9%67.0%71.3% (computed)48.7%
Operating margin-625.9%n/mn/m-585.8%
Net margin-545.2%n/mn/m-560.3%
Net income-$6.21M-$22.70M-$13.40M-$7.12M
EPS (Diluted)-$9.13-$1.29-$1.20-$0.09
Operating cash flow-$4.02M-$18.64M-$9.90M-$4.79M
Free cash flown/a-$18.89M-$10.29M-$4.91M
Cash & equivalents$28.18M$4.66M$24.71M$405.0K
Total assets$34.75M$10.26M$32.47M$8.75M
Total liabilities$5.05M$4.59M$29.63M$2.42M
Shareholders' equity$29.71M$5.67M$2.84M$6.33M
Return on year-end equity-20.9%-400.1%-471.4%-112.5%
Shares outstandingn/an/a14.50M80.88M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearChina SXT Pharmaceuticals, Inc.Longeveron Inc.Dare Bioscience, Inc.IGC Pharma, Inc.
Latest$1.14M
Ended 2026-03-31
$1.20M
Ended 2025-12-31
$1.03M
Ended 2025-12-31
$1.27M
Ended 2025-03-31
1 year earlier$1.74M
Ended 2025-03-31
$2.39M
Ended 2024-12-31
$9.8K
Ended 2024-12-31
$1.34M
Ended 2024-03-31
2 years earlier$1.93M
Ended 2024-03-31
$709.0K
Ended 2023-12-31
$2.81M
Ended 2023-12-31
$911.0K
Ended 2023-03-31
3 years earlier$1.97M
Ended 2023-03-31
$1.22M
Ended 2022-12-31
$10.00M
Ended 2022-12-31
$397.0K
Ended 2022-03-31
4 years earlier$2.60M
Ended 2022-03-31
$1.31M
Ended 2021-12-31
$0
Ended 2021-12-31
$898.0K
Ended 2021-03-31